Meng Wenjun, Pan Lu, Huang Li, Li Qing, Sun Yi
Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
West China School of Medicine, Sichuan University, Chengdu, China.
Front Oncol. 2024 Aug 23;14:1464242. doi: 10.3389/fonc.2024.1464242. eCollection 2024.
With the development of comprehensive treatment, locoregional transarterial chemotherapy has become an alternative conversion therapy, palliative therapy, and neoadjuvant therapy for many solid malignant tumors. Locoregional transarterial chemotherapy, which is most frequently used for treating liver cancer, has the characteristics of high regional efficacy and few systemic adverse reactions. In recent years, the number of relevant reports of locoregional chemotherapy for treating initially inoperable colorectal cancer (CRC), including non-metastatic and metastatic CRC, has gradually increased. However, the specific treatment options for such locoregional therapy are not the same, and its indications, medication regimens and combined treatments have not reached any consensus. In this review, the application status of locoregional transarterial chemotherapy in primary and metastatic CRC patients has been reviewed and summarized to provide a reference for future clinical work and scientific research.
随着综合治疗的发展，局部动脉化疗已成为许多实体恶性肿瘤的替代转化治疗、姑息治疗和新辅助治疗方法。局部动脉化疗最常用于治疗肝癌，具有局部疗效高、全身不良反应少的特点。近年来，关于局部化疗治疗初始不可切除结直肠癌（CRC）（包括非转移性和转移性CRC）的相关报道数量逐渐增加。然而，这种局部治疗的具体治疗方案并不相同，其适应证、用药方案和联合治疗尚未达成任何共识。在本综述中，对局部动脉化疗在原发性和转移性CRC患者中的应用现状进行了综述和总结，为未来的临床工作和科研提供参考。
